Additional approval requirement in China pains drug industry
This article was originally published in SRA
Executive Summary
Between 50 and 60 new drugs cleared for clinical development in China face an additional layer of regulatory approval, which could further delay product approvals by 30 months, warns multinational big pharma trade group RDPAC.